[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.159.27. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 429
Citations 0
Comment & Response
November 24, 2015

Cost-effectiveness of Statin Therapy for ASCVD—Reply

Author Affiliations
  • 1Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
  • 2Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2015;314(20):2191-2192. doi:10.1001/jama.2015.12928

In Reply We agree with the points Drs Luo and Kesselheim raised and have the following points to add regarding our cost-effectiveness analysis in light of these issues.

As Luo and Kesselheim noted, we used the weighted average of the lowest Red Book wholesale acquisition costs in our base-case analysis, but also paid particular attention to the price of statins when presenting our results. Specifically, we presented (1) separate cost-effectiveness analysis tables for blended generic/branded and generic-only drug prices and (2) a 1-way sensitivity analysis figure showing the optimal ASCVD treatment threshold as a function of drug cost for 3 separate cost-effectiveness thresholds ($50 000/QALY, $100 000/QALY, and $150 000/QALY).

First Page Preview View Large
First page PDF preview
First page PDF preview
×